#5-01E. Unveiling Behçet’s Syndrome: Pathogenesis and Targeted Therapies in Systemic Vasculitis (NEJM, 2024)

Do you often encounter diverse, treatment-resistant inflammatory presentations such as recurrent mucocutaneous ulcers combined with ocular or vascular involvement? Today's episode focuses on Behçet’s syndrome, a chronic, relapsing multisystem inflammatory condition1. This comprehensive review highlights how recent immunogenetic discoveries, notably regarding HLA-B*51, have evolved its classification into a primary systemic vasculitis, detailing its pathogenesis, varied clinical manifestations, and the latest management strategies. The most pivotal clinical insight is that molecularly targeted therapies, particularly TNF inhibitors, have significantly improved the prognosis for patients with severe major organ involvement, preventing irreversible damage and blindness. However, when critically appraising this field, clinicians must recognize the ongoing lack of standardized outcome measures for disease activity and the scarcity of high-level evidence regarding the optimal duration of immunosuppressive therapies. For practicing physicians, this paper is highly relevant as it offers an updated, multidisciplinary framework for tailoring treatments with emerging biologics, ultimately helping you better manage refractory cases and mitigate life-threatening complications in your daily clinical practice.

Citation: Saadoun D, Bodaghi B, Cacoub P. Behçet’s Syndrome. The New England Journal of Medicine. 2024. DOI: 10.1056/NEJMra2305712

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.